56 reports

Figure ##: List of Figures Figure No.

  • Remote Monitoring
  • Respiratory Disease
  • World
  • Market Size
  • Halma plc

FEV## is the amount of air one can force from lungs in one second.

  • Respiratory Disease
  • World
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici S.p.A.
  • levels has been leading to a significant increase in the prevalence of the patients with various respiratory diseases.

Others: ##.

  • Asthma
  • Respiratory Disease
  • World
  • Market Size
  • Medtronic, Inc.

Figure ##. ##.

  • Respiratory Disease
  • World
  • Forecast
  • Market Size
  • Bio-Rad Laboratories, Inc.
  • Global venturi masks market in asthma 2016-2021 ($ millions)

You can easily book an appointment with one online.

  • Hospital
  • Oxygen Device
  • Respiratory Disease
  • World
  • Forecast

Such abnormality lead to increased chances of coronary artery diseases, heart attack or stroke.

  • Respiratory Disease
  • Market Size
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • 6.1.2 Financial Overview

One lung is lavaged in first procedure followed by lavage of opposite lung one or two weeks later.

  • Respiratory Disease
  • World
  • Forecast
  • Market Size
  • Mast Therapeutics, Inc.

You can easily book an appointment with one online.

  • Respiratory Device
  • Respiratory Disease
  • World
  • Forecast
  • Teleflex Incorporated

No one knows why.

  • Asthma
  • Cardiovascular Disease
  • Healthcare
  • Respiratory Disease
  • United States

Pulmonary hypertension may sometimes lead to chronic illnesses such as renal failure, heart failure, aneurysm, heart attack, or stroke.

  • Respiratory Disease
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Bibliography
  • Bibliography

term=GLOW+##& rank=## [Accessed ## March 2016].

  • Respiratory Disease
  • European Union
  • Japan
  • North America
  • United States
  • LEADING CAUSES OF EARLY DEATH, 1990 VS. 2017

Studies show that around ## to ##% of patients with heart disease have OSA, and nearly ##% of stroke patients suffer from the disease.

  • Intensive Care
  • Respiratory Disease
  • North America
  • United States
  • ResMed Inc.

IT WAS ALSO UNDER DEVELOPMENT FOR STROKE CAUSED BY BLOCKAGE OF BLOOD VESSELS.

  • Blood Disease
  • Cell Therapy
  • Respiratory Disease
  • Therapy
  • Bristol-Myers Squibb Company
  • PRODUCTS UNDER DEVELOPMENT BY UNIVERSITIES/INSTITUTES, H2 2018 (CONTD..1), H2 2018

IT WAS ALSO UNDER DEVELOPMENT FOR STROKE CAUSED BY BLOCKAGE OF BLOOD VESSELS.

  • Blood Disease
  • Cell Therapy
  • Respiratory Disease
  • Therapy
  • Bristol-Myers Squibb Company

## Arteriovenous Malformations ## Bone Tumor ## Stroke ## Superficial Femoral Artery Disease ## Tumor ## Varicose Veins ## Emphysema ## Hepatocellular Carcinoma ## Metastatic Colorectal Cancer ## Metastatic Live

  • Compression Therapy
  • Hospital
  • Respiratory Disease
  • Therapy
  • BTG plc
  • ALTEPLASE - DRUG PROFILE
  • BRONCHITIS - PIPELINE BY ASTRAZENECA PLC, H1 2018

The results of CLEAR III showed tPA treatment significantly decreased mortality in one of the worst forms of hemorrhagic stroke.

  • Respiratory Disease
  • Therapy
  • United States
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • OTC
  • Respiratory Disease
  • Salicylic Acid
  • World
  • Product Initiative

Mirrored commercial units - one for BioPharmaceuticals and one for Oncology.

  • Hospital
  • Respiratory Disease
  • United States
  • Company
  • Vectura Group plc

One unit refers to one bedside capnograph.

  • Clinical Trial
  • Medical Device
  • Respiratory Disease
  • United States
  • Masimo Corporation
  • ALTEPLASE - DRUG PROFILE
  • BRONCHITIS - PIPELINE BY ASTRAZENECA PLC, H2 2018

The results of CLEAR III showed tPA treatment significantly decreased mortality in one of the worst forms of hemorrhagic stroke.

  • Allergy Immunotherapy
  • Respiratory Disease
  • Therapy
  • United States
  • Product Initiative
  • Malignant Pleural Effusion - Pipeline by Genelux Corp, H2 2018
  • Malignant Pleural Effusion - Pipeline by Biogen Inc, H2 2018

The stable disease was seen in colorectal rectal cancer (n=##), head and neck (n=##), chondrosarcoma (n=##), parotid (n=##), thyroid (n=##), esophageal (n=##) and renal cell carcinoma (n=##).

  • Pathology
  • Respiratory Disease
  • Therapy
  • United States
  • Amgen Inc.
  • Malignant Pleural Effusion - Pipeline by Advantagene Inc, H1 2018
  • Malignant Pleural Effusion - Pipeline by Biogen Inc, H1 2018

It has several products candidates targeting various indications such as MS, Parkinson' s disease, Alzheimer' s disease and idiopathic pulmonary fibrosis, stroke, among others.

  • Pathology
  • Respiratory Disease
  • Therapy
  • United States
  • Genelux Corporation

Mecasermin supplies recombinant-DNA-origin IGF-##, which binds to the Type I IGF-## receptor.

  • Clinical Trial
  • Respiratory Disease
  • Therapy
  • United States
  • Product Initiative

WERE $##. ## BILLION, INCREASING ## PERCENT.

  • Clinical Trial
  • Respiratory Disease
  • Australia
  • Company
  • Vectura Group plc
  • ASTHMA - PIPELINE BY XENCOR INC, H2 2018
  • CK-2018571 - DRUG PROFILE

In January 2011, preclinical study on ischemic stroke was initiated.

  • Asthma
  • Respiratory Disease
  • United States
  • Company
  • AstraZeneca PLC

The prominent features of this report are - ##.

  • Drug Development
  • Respiratory Disease
  • World
  • Product Initiative
  • Otsuka Pharmaceutical Co., Ltd.
  • ASTHMA - PIPELINE BY CIRCASSIA PHARMACEUTICALS PLC, H1 2018
  • CIRCASSIA PHARMACEUTICALS PLC

Findings showed that masitinib reduced stroke-related brain infarct size in an animal model of stroke.

  • Asthma
  • Pharmaceutical
  • Research And Development
  • Respiratory Disease
  • AstraZeneca PLC

Mecasermin supplies recombinant-DNA-origin IGF-##, which binds to the Type I IGF-## receptor.

  • Clinical Trial
  • Respiratory Disease
  • Therapy
  • United States
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Respiratory Disease
  • Therapy
  • World
  • Product Initiative

Despite current standard of care, nearly ## percent of people age ## or older with diabetes die from some form of heart disease, and ## percent die of stroke.

  • Immunotherapy
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Regeneron Pharmaceuticals, Inc.